Our findings suggest that the SREBF2 gene (rs2267443) and the INSIG2 (rs11123469) polymorphisms may contribute to the underlying pathophysiology of dyslipidemia in patients receiving risperidone, which supports a previous study that risperidone exposure affected the SREBP-regulated lipid biosynthesis and other lipid homeostasis pathways [17]. Here, SREBF2 is linked to metabolic syndrome.